aibio
Financings ·
Immix Biopharma prices $125 million stock offering at $11.00 a share
The company is selling 11,363,637 shares through J.P. Morgan. Proceeds will fund development of its CAR-T candidate NXC-201.
IMMX Immix Biopharma, Inc.
Immix Biopharma (IMMX) news IMMX offering news
Latest Immix Biopharma news
We have not published a story on Immix Biopharma yet. When there is news, it will appear here.
Immix Biopharma annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $16.3 million | $11.3 million |
| Net income (loss) | -$29.4 million | -$21.6 million |
| Cash from operations | -$23.9 million | -$14.6 million |
| Cash and equivalents | $93.9 million | $17.7 million |
| Short-term investments | $6.5 million |
Questions about Immix Biopharma
Has Immix Biopharma raised money recently?
Our latest story on this, dated Sep 29, 2026: "Immix Biopharma prices $125 million stock offering at $11.00 a share". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Immix Biopharma?
Immix Biopharma, Inc. trades under the ticker IMMX on NASDAQ.
Where is Immix Biopharma listed?
Immix Biopharma, Inc. is listed on NASDAQ.
What is the SEC CIK of Immix Biopharma?
The SEC Central Index Key (CIK) for Immix Biopharma, Inc. is 1873835. Its filings are on SEC EDGAR.
How many shares does Immix Biopharma have outstanding?
71,539,314 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-07.
Which country or territory is Immix Biopharma listed under?
Our directory records Immix Biopharma, Inc. under United States.
What does Immix Biopharma do?
Our directory classifies Immix Biopharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Immix Biopharma?
The ISIN recorded for Immix Biopharma, Inc. is US45258H1068.
Does aibio.space cover Immix Biopharma?
aibio.space lists Immix Biopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Immix Biopharma incorporated?
SEC records list its state or country of incorporation as DE.
Is Immix Biopharma profitable?
Immix Biopharma, Inc. reported a net loss of $29.4 million for the fiscal year ended Dec 31, 2025, and used $23.9 million of cash in operations, per its annual report to the SEC.
How much does Immix Biopharma spend on research and development?
$16.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Immix Biopharma have?
$232.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Immix Biopharma (IMMX) stock news?
Our latest story on Immix Biopharma, dated Sep 29, 2026: "Immix Biopharma prices $125 million stock offering at $11.00 a share". The company is selling 11,363,637 shares through J.P. Morgan. Proceeds will fund development of its CAR-T candidate NXC-201. Source.
What is Immix Biopharma's market cap?
We do not publish live share prices. In its annual report, Immix Biopharma, Inc. put the market value of shares held by non-affiliates (public float) at $35.7 million as of Jun 30, 2025.
Investor discussion: Immix Biopharma
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Stock chart
SEC filings and registration
- SEC name
- Immix Biopharma, Inc.
- CIK
- 1873835
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- IMMX (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- <br>Emerging growth company
- Business address
- 11400 WEST OLYMPIC BLVD., LOS ANGELES, CA, 90064
- Phone
- (888) 958-1084
- Shares outstanding
- 71,539,314 as of 2026-08-03 (10-Q filed 2026-08-07)
- Former names
- Immix Biopharma, Inc.
Recent filings
Listing details
- Company
- Immix Biopharma, Inc.
- Ticker
- IMMX
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US45258H1068
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction